2-Methylthioadenosine diphosphate trisodium  (Synonyms: 2-Methylthio-ADP trisodium)

2-Methylthioadenosine diphosphate trisodium is a potent purinergic P2Y receptors agonist, with EC₅₀s of 19, 6.2, and 5 nM for human P2Y13, mouse P2Y13 and human P2Y12, respectively. 2-Methylthioadenosine diphosphate trisodium has pEC₅₀s of 8.29 and 5.75 for human P2Y1 and rat P2Y6, respectively. 2-Methylthioadenosine diphosphate trisodium induces platelet aggregation and shape change, and inhibits cyclic AMP accumulation in platelets exposed to prostaglandin E1^[1][2][3].

2-Methylthioadenosine diphosphate trisodium (2-Methylthio-ADP trisodium) is a powerful aggregating agent for human platelets. 2-Methylthioadenosine diphosphate trisodium is also a powerful inhibitor of the accumulation of cyclic AMP in intact platelets exposed to PGE1 and a phosphodiesterase inhibitor^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

539.24

C₁₁H₁₄N₅Na₃O₁₀P₂S

475193-31-8

液体

Colorless to light yellow

Room temperature in continental US; may vary elsewhere.

Solution, -20°C, 2 years

• [1]. Zhang FL, et al. P2Y(13): identification and characterization of a novel Galphai-coupled ADP receptor from human and mouse. J Pharmacol Exp Ther. 2002;301(2):705-713.  [Content Brief]

  [2]. Sak K, et al. A retrospective of recombinant P2Y receptor subtypes and their pharmacology. Arch Biochem Biophys. 2002;397(1):131-136.  [Content Brief]

  [3]. Macfarlane DE, et al. 2-Methylthioadenosine[beta-32P]diphosphate. An agonist and radioligand for the receptor that inhibits the accumulation of cyclic AMP in intact blood platelets. J Clin Invest. 1983;71(3):420-428.  [Content Brief]